RSI společnosti Beam Therapeutics
Jaká je hodnota metriky RSI společnosti Beam Therapeutics?
Hodnota metriky RSI společnosti Beam Therapeutics Inc. je 43.55
Jaká je definice metriky RSI?
Index relativní síly (Relative strength index - RSI 14) je technický ukazatel, který se řadí mezi momentum indikátory a měří rychlost a změnu ceny. Jeho hodnota se pohybuje mezi 0 a 100 a používá se k charakterizování překupovaného a přeprodaného stavu.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Beam Therapeutics
Čemu se věnuje společnost Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Firmy s metrikou rsi podobnou společnosti Beam Therapeutics
- Hodnota metriky RSI společnosti Buru je 43.53
- Hodnota metriky RSI společnosti Samkrg Pistons and Rings je 43.53
- Hodnota metriky RSI společnosti New Leaf Ventures Inc je 43.54
- Hodnota metriky RSI společnosti Scholar Rock Corp je 43.54
- Hodnota metriky RSI společnosti East West je 43.54
- Hodnota metriky RSI společnosti Yield Go je 43.54
- Hodnota metriky RSI společnosti Beam Therapeutics je 43.55
- Hodnota metriky RSI společnosti Coeur Mining Inc je 43.56
- Hodnota metriky RSI společnosti Upland Resources je 43.56
- Hodnota metriky RSI společnosti ArcPacific Resources je 43.56
- Hodnota metriky RSI společnosti 1+1 Ag Inh O.N je 43.56
- Hodnota metriky RSI společnosti Keyne Ltd je 43.56
- Hodnota metriky RSI společnosti ZCCM Investments Plc je 43.56